Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 Jan;20(1):29-37.
doi: 10.1007/s12094-017-1809-9. Epub 2017 Dec 13.

SEOM clinical guidelines for endometrial cancer (2017)

A Santaballa  1 , X Matías-Guiu  2 , A Redondo  3 , N Carballo  4 , M Gil  5 , C Gómez  6 , M Gorostidi  7 , M Gutierrez  8 , A Gónzalez-Martín  9
Affiliations
Practice Guideline

SEOM clinical guidelines for endometrial cancer (2017)

A Santaballa et al. Clin Transl Oncol. 2018 Jan.

Erratum in

Abstract

Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defined and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge of the molecular abnormalities in EC have permitted the development of promising targeted therapies.

Keywords: Adjuvant treatment; Chemotherapy; Endometrial cancer; Radiotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Figures

Fig. 1
Fig. 1
Adjuvant treatment for endometrial cancer. LVSI lymphovascular invasion, VBT vaginal brachytherapy, CT chemotherapy, PRT pelvic radiotherapy, EEC endometrioid endometrial cancer, EC endometrial cancer. Modified from endometrial cancer algorithms that refers to Colombo et al. [7]
See this image and copyright information in PMC

References

    1. Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2013;34(3):490–497. doi: 10.1002/humu.22262. - DOI - PMC - PubMed
    1. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261–269. doi: 10.1056/NEJMoa052627. - DOI - PubMed
    1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumors of the female reproductive organs. WHO classification of tumors. Lyon: IARC press; 2014.
    1. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology. 2013;62:111–123. doi: 10.1111/his.12053. - DOI - PubMed
    1. Cancer Genome Atlas Research Network. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. doi: 10.1038/nature12113. - DOI - PMC - PubMed

Publication types